yalemedicine

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in ...

This first-in-human, Phase 1/2 study will aim to obtain safety and tolerability data when AVZO-1418 is administered intravenously to patients with locally advanced or metastatic epithelial solid ...
clinicaltrialvanguard

A Maternal GBS Vaccine Just Cleared Phase 1/2. Here’s What the Trial Design Tells Us About the Regulatory Gauntlet Ahead.

Picture the scene: a regulatory affairs lead at a maternal vaccine program opens a fresh set of Phase 1/2 data on a Monday morning. The tables show robust immunogenicity responses in pregnant women.
RTTNews

Phase 1, 2, And 3 Clinical Trials Explained: What Every Biotech Investor Needs To Know

Clinical trials are a key driver of biotech stocks. Every new therapy must pass through a series of testing, Phase 1, Phase 2, and Phase 3, before it is approved and available to patients. Each phase ...
MarketScreener

Arvinas, Inc. Announces First Participant Dosed in Phase 1/2 Clinical Trial of Arv-6723

Arvinas, Inc. announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade ...
FierceBiotech

Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes

A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for patients with both type 2 diabetes and obesity. The ...
MarketScreener

Revolution Medicines Publishes Phase 1/2 Clinical Data on Rasonque (Daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines announced that The New England Journal of Medicine has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS (ON) ...
RTTNews

Xilio Advances XTX501; FDA Clears IND For Phase 1/2 Trial

Xilio Therapeutics, Inc. (XLO), a clinical-stage biotechnology company developing masked immuno-oncology therapies, reported second-quarter 2026 financial results and business updates, highlighting ...
gsk

GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)

GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant (a P2X3 receptor antagonist) in ...
Washington Technology

DOD suspends CMMC Phase 2, launches 60-day ‘reform’ review

Citing prohibitive costs for small and mid-size contractors, the Defense Department will keep Phase 1 self-assessments in place while a new task force studies the cyber and supply chain security ...
ir.ionis.com

Release Details

CARLSBAD, Calif.--(BUSINESS WIRE)--Jul. 13, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an ...
Business Wire

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational ...